Latest Glaxosmithkline Plc (GSK) Headlines Bett
Post# of 51
Posted On: 03/14/2014 12:25:59 AM
Latest Glaxosmithkline Plc (GSK) Headlines
Better Dividend: GlaxoSmithKline vs. AbbVie
Dan Carroll, The Motley Fool - Motley Fool - Thu Mar 13, 1:30PM CDT
Big pharma's one of the best industries for investors hungry for high-yielding dividends. Some of the biggest stocks in this sector offer great dividends and stable cash flows, and both GlaxoSmithKline and AbbVie rank among the top names in the...
Appointments, Regulatory Approvals, Conference Participation Schedule, Acquisitions, and Increased Stake - Analyst Notes on Perrigo, Zoetis, ISIS, GSK, and AstraZeneca
PR Newswire - Thu Mar 13, 7:31AM CDT
Today, Analysts Review released its analysts' notes regarding Perrigo Company (NYSE: PRGO), Zoetis Inc. (NYSE: ZTS), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), GlaxoSmithKline plc (NYSE: GSK), and AstraZeneca plc (NYSE: AZN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Patient Recruitment Completes in Landmark RELVAR(R)/BREO(R) ELLIPTA(R) Study to Understand Mortality and MorbidITy (SUMMIT) in COPD
Marketwire - Thu Mar 13, 7:02AM CDT
GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that recruitment of patients into the "Study to Understand Mortality and MorbidITy", known as SUMMIT, has completed enrolment. The aim of this study, which has now enrolled approximately 16,000 patients, is to determine the impact of Relvar(R)/Breo(R) Ellipta(R) (fluticasone furoate 'FF'/vilanterol 'VI') on all cause mortality amongst patients with moderate chronic obstructive pulmonary disease (COPD) who have cardiovascular disease (CVD) or are at increased risk for CVD.
Concise Analysis of the International Orphan Drugs Industry
M2 - Thu Mar 13, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdwn77/orphan_drugs) has announced the addition of the "Concise Analysis of the International Orphan Drugs Industry " report to their offering. This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Japan, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 113 companies including many key and niche players such as: - AbbVie Inc. - Actelion Pharmaceuticals Ltd. - Amgen Inc. - AstraZeneca plc - Bayer HealthCare AG - Biogen Idec Inc. - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Celgene Corporation - CEL-SCI Corporation - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Johnson & Johnson - Merck & Co. Inc. - Merck Serono International S.A. - Novartis AG - Pfizer Inc. - Recordati S.p.A. - Orphan Europe - Sanofi SA - Genzyme Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers And Inhibitors 3. Challenges To Orphan Drug Development 4. Current Market Trends 5. Breakthroughs In Orphan Disease Treatment - A Ray Of Hope 6. Regulatory Scenario 7. Product Overview 8. Recent Orphan Designations & Approvals 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Japan 3. Europe 4. Rest Of World IV. Competitive Landscape Total Companies Profiled: 113 (including Divisions/Subsidiaries - 121) - The United States (61) - Canada (4) - Japan (9) - Europe (42) - France (8) - Germany (3) - The United Kingdom (4) - Italy (4) - Rest of Europe (23) - Asia-Pacific (Excluding Japan) (3) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/kd...phan_drugs
Concise Analysis of the International Oral Hygiene Market - Forecast to 2016
M2 - Thu Mar 13, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dqpd5c/global_oral) has announced the addition of the "Concise Analysis of the International Oral Hygiene Market - Forecast to 2016" report to their offering. One of the main trends witnessed in the Global Oral Hygiene market is the increase in mergers and acquisitions. Vendors are currently opting for the acquisitive route to increase their global presence, expand their product portfolio, and achieve economies of scale in manufacturing. Therefore, they are able to focus better on product innovation and increase their profit margins by collaborating with each other. For instance, Colgate-Palmolive acquired complete stakes of Professional Oral care Products Ltd., a Goa based firm manufacturing and supplying toothpaste to the company in 2010. To venture into new emerging countries, giant vendors of oral hygiene products can merge into or acquire small local vendors thus, gaining more market share. According to the report, one of the main factors driving the market is the increasing demand for age specific products. Fluoride containing mouthwashes are made specifically for adults as they can be harmful to children because there are chances that children might ingest it. Further, the report states that one of the main challenges is the increase in product recalls. For instance, in May 2011, Sensodyne Repair and Protect brand of GSK had to recall thousands of toothpaste tubes from the market as they found some grittiness in the paste that led to bleeding gums. The report also includes a discussion of the other vendors operating in this market. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Market Segmentation 8. Distribution Channel 9. Geographical Segmentation 10. Key Leading Countries 11. Vendor Landscape 12. Buying Criteria 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Key Vendor Analysis Companies Mentioned: - Colgate-Palmolive Co. - GlaxoSmithKline plc - Johnson & Johnson Inc. - Procter& Gamble Co. - Chattem Inc. - Dentsply International Inc. - Lion Corp. - Unilever plc. For more information visit http://www.researchandmarkets.com/research/dq...lobal_oral
Pharmacovigilance Market Research Report - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Thu Mar 13, 4:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rs95v7/pharmacovigilance) has announced the addition of the "Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. A rising tide of regulatory expectations, tougher inspection regime and instant need of patient reporting has provided the much needed impetus for the growth of the pharmacovigilance market. An upsurge in number of acute and chronic diseases has consequently led to a rise in number of drug consumption, which has also elicited a growth in the number of adverse drug events and drug toxicity cases. Moreover, several high-profile safety issues, regulatory warnings, large volume of events to be reviewed along with negative media coverage have compelled the pharmaceutical players to take support of various outsourcing services. There are two major outsourcing services opted by these pharmaceutical players i.e. traditional CROs and BPOs. These outsourcing services not only provide cost savings but also helps in bringing process efficiency. Pharmaceutical companies are now forming long term partnership with the CROs and BPOs to share the costs involved in PV process right from drug discovery to post marketing approvals. In addition, PV requires skilled resources with excellent language skills and strong knowledge pertaining to case reporting. The research report on pharmacovigilance provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of pharmacovigilance market on the bases of clinical trials phases i.e. Phase I to III and post marketing surveillance (PMS). We have also mapped the trend for preference of the pharmaceutical players for in-house and outsourcing in our chapter by type of service. The global pharmacovigilance market has been segmented based on all the above mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in term of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has also been provided along with market size estimations. The report exclusively studies the aforementioned segments with respect to geography. Under geographic section we have covered four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (ROW). The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global pharmacovigilance market. The section also covers opportunities and market attractiveness analysis of the geographical regions. The report concludes with the competitive landscape and company profiles of major market players. These market players have been profiled on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Key Topics Covered: Introduction Executive Summary Global Pharmacovigilance Market Dynamics Global Pharmacovigilance Market, by Clinical Trial Phases Global Pharmacovigilance Market, By Type of Methods Global Pharmacovigilance Market, by Type of Service Providers Global Pharmacovigilance Market, by Geography Global Pharmacovigilance Market Share Analysis Recommendations Company Profiles List of Figures List of Tables Companies Mentioned - Accenture, Plc - Bristol-Myers Squibb - Clinquest Group B.V. - Cognizant Technology Solutions - Covance, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline (GSK) - iGATE Corporation - iMEDGlobal Corporation - inVentiv Health Inc. - ICON, Plc - Infosys - Johnson and Johnson - Novartis International AG - OptumInsight, Inc. - PRA International, Inc. - Parexel International Corporation - Pfizer, Inc. - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Quantum Solutions India - Quintiles Transnational Corporation - Sanofi Aventis - Synowledge LLC - United BioSource Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/rs...ovigilance About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Looking for Bargain Biotechs? Consider Small-Cap Vaccine Makers
George Budwell, The Motley Fool - Motley Fool - Wed Mar 12, 5:30PM CDT
Growth and value are two words that have completely fallen out of the biotech lexicon of late. The adjectives 'bubble' and 'expensive' have instead taken their place, when investors talk biotech. And with the average biotech price to earnings ratio...
Watch for GlaxoSmithKline to Potentially Rebound After Falling 1.20% Yesterday
Comtex SmarTrend(R) - Wed Mar 12, 5:26PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $54.83 to a high of $55.23. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $55.12 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Look for Shares of GlaxoSmithKline to Potentially Rebound after Yesterday's 1.20% Sell Off
Comtex SmarTrend(R) - Wed Mar 12, 5:25PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $54.83 to a high of $55.23. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $55.12 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Glaxo Strengthens Indian Presence - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 5:25PM CDT
GlaxoSmithKline increased its holding in its pharmaceuticals subsidiary in India to 75% through a voluntary open offer.
Bright Outlook at Ligand - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 10:30AM CDT
Ligand provided a rosy outlook at the 2014 Roth Healthcare conference.
The Saudi Arabian Healthcare Sector is Anticipated to Expand at a CAGR of Around 8.7% During 2013-2017
M2 - Wed Mar 12, 10:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/npc4rs/saudi_arabian) has announced the addition of the "Saudi Arabian Healthcare Outlook to 2017" report to their offering. On the back of rising population, prevalence of lifestyle changes & infectious diseases, longer life expectancy & improving healthcare infrastructure, among others, Saudi Arabian Healthcare Sector is witnessing a significant growth over the past few years. The government and health regulatory authorities in the country have been taking keen interest in developing and enhancing healthcare infrastructure for increased accessibility. This report is an outcome of extensive research and analysis of the Saudi Arabian Healthcare Industry. It provides an in-depth analysis of the contributions by MoH, private and other public sectors to the country's healthcare industry, which includes study of existing healthcare infrastructure; hospital beds capacity and forecasted demand; healthcare workforce; etc. for each segment. Also, the research analyzes various crucial factors, like medical test rates in private hospitals and consultancy fees to provide an in-depth knowledge about the industry to potential investors. The report further studies the Kingdom's medical devices and pharmaceuticals market. In the coming years, the country's pharmaceutical industry is expected to witness strong growth. The authors found that this industry was one of the highly prolific healthcare sectors due to rising prevalence of lifestyle diseases, like obesity, diabetes and cardiovascular ailments. The report includes detailed information about the domestic pharmaceutical market and the country's imports. In medical device segment, presently the country has low manufacturing capabilities, but the market is growing tremendously, supported by government. The report further discusses how growing consolidation, application of e-health and m-health, and favorable regulations are influencing the industry's growth. It also covers a regional analysis of the country's healthcare industry to give an idea about the region, exhibiting better opportunity for investment to customers. Finally, the study covers a competitive landscape, which includes the country's prominent pharmaceutical players and hospitals, to help clients understand the market, its structure and progress in the coming years. Companies Mentioned: - GlaxoSmithKline - Pfizer Inc. - SPIMACO - Sanofi-Aventis - TABUK Pharmaceutical Manufacturing For more information visit http://www.researchandmarkets.com/research/np...di_arabian About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update
M2 - Wed Mar 12, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p5vwnh/pharmapoint) has announced the addition of the "PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update" report to their offering. New Serogroup B Vaccines to Claim Half of Meningococcal Vaccines Market by 2022 Upcoming and long-awaited market entries for Novartis' Bexsero and Pfizer's MnB rLP2086 will prompt significant growth in the meningococcal vaccines market over the next decade, states research and consulting firm The authors. According to the report, the arrival of these eagerly awaited serogroup B vaccine will drive combined revenue for meningococcal vaccines across the US, France, Germany, Italy, Spain, the UK, Japan, Australia, and Brazil, from $1.2bn in 2012 to just over $2bn in 2022, increasing by 65%. Novartis' Bexsero, which received approval from the European Medicines Agency (EMA) in January, is forecast to produce global sales of over $330m by 2022, while Pfizer's MnB rLP2086, which is expected to launch in the US in 2017 and in the EU the following year, is forecast to reach total revenue of over $700m by 2022. Combined, these two products are expected to dominate the meningococcal vaccines market by the end of the forecast period, accounting for a 52% share. According to Dr Christopher Pace, The authors's analyst covering infectious disease: Despite legitimate concerns from policymakers regarding the cost-effectiveness of adding an additional vaccine to already-crowded immunization schedules, serogroup B incorporation will be well received by prescribers and patients, alike. Novartis and Pfizer are expected to dominate this segment of the market, with their respective products responsible for the majority of global market growth over the next decade. The authors's report states that the cost-effectiveness of meningococcal vaccines is a universal barrier to global market growth, with the inherently high cost per dose and relatively low incidence rates of meningococcal disease leading to increased government skepticism in the face of new vaccine launches and immunization program expansions. Dr Pace believes that while these concerns are not expected to significantly prohibit the adoption of serogroup B vaccines, such as Bexsero and MnB rLP2086, government assessment of cost-effectiveness is considered to be a primary determinant of a vaccine's commercial success. Key Topics Covered - Table of Contents - Introduction - Disease Overview - Epidemiology - Disease Management - Competitive Assessment - Opportunity and Unmet Need - Pipeline Assessment - Current and Future Players - Market Outlook - Appendix Companies Mentioned - Baxter - GlaxoSmithKline - Novartis - Nuron Biotech - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/p5...harmapoint About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
As Raleigh NC Makes the Forbes List of America's Fastest Growing Cities, Mark Steward, Realtor with DT&Company, Says, "Come for the Jobs, Stay for the Lifestyle"
PRWeb - Wed Mar 12, 3:40AM CDT
With annual job growth of 2.9%, people are migrating to Research Triangle Park also known as the RTP in the Raleigh-Durham area in North Carolina. Thousands of families are taking a hard look at this region and planning their relocation to the Triangle. This growth can be attributed to many surprising advantages that the region offers. According to Forbes, after talking with New York-based research firm Ipreo, it became clear the company was looking to expand into a new office, and searched nation-wide for the perfect location. "The primary goal was access to talent," says O'Hara Macken, an EVP and managing director, "and the [Research] Triangle was our top choice in the U.S." Ipreo, which provides data, software, and intelligence to the capital markets and public companies, opened an outpost in Raleigh, N.C. last year, moved 70 employees from New York and Bethesda, Md., hired 80 North Carolina locals, and plans to hire 100 more. (Forbes, The best place for business and careers, February 14, 2014)
The Cancer Monoclonal Antibodies Market is Estimated at US$ 24 Billion, and is expected to Grow to Around US$ 34 Billion by 2017
M2 - Tue Mar 11, 10:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ghw3bj/cancer_monoclonal) has announced the addition of the "Cancer Monoclonal Antibodies Market Forecast to 2017" report to their offering. Cancer, one of the leading causes of death worldwide, affected approximately 13 Million people in 2012 and this figure is expected to grow to 17 Million by 2020. The dramatic increase in the size of the potential cancer market has prompted pharmaceutical players to invest in the oncology sector with major focus on monoclonal antibodies. Monoclonal antibodies identify cancer cells, bind to proteins on their surface, and stimulate an immune response so are very specific to targets. Various monoclonal antibodies for treatment of cancer are available in the market and many more are in the pipeline. The report, in particular, provides an insight to the global burden of cancer, with detailed breakdown of incidences by type and geography. It not only estimates the current burden but also makes future predictions. There is an exhaustive overview of the monoclonal technology, helping the client understand the various types of antibodies and the diverse types of cancer therapies which make use of mAbs. In this report, the authors have profiled every anti-cancer monoclonal antibody available in the market and estimated the current and future market of five of them. The report covers major trends which are driving the current market and a country level analysis of the status of cancer mAbs. Through this pipeline analysis of the various mAbs, it has been revealed that majority of the mAbs in the pipeline are in phase III trials with most of them devoted to Solid Tumor, Lung Cancer, Breast Cancer, and NHL. The approval of these drugs will drive a major change in the market in terms of market share of current drugs. Companies Mentioned: - Amgen - Bristol-Myers Squibb - Eli Lilly - Genmab - GlaxoSmithKline - Roche - Seattle Genetics - Spectrum Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/gh...monoclonal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Wider Q4 Loss at Dynavax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:10AM CDT
Dynavax Technologies reported a loss of 9 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 7 cents.
Awards Recognise GlaxoSmithKline, Henkel, MondelA"z International, Tesco and the US Department of Veterans Affairs for e-Invoicing Best Practice
PR Newswire Europe - Tue Mar 11, 4:32AM CDT
LONDON, March 11, 2014 /PRNewswire/ --
A HIV shot could replace pills
at Investor's Business Daily - Mon Mar 10, 5:46PM CDT
Daily pills like Gilead's (GILD) Truvada can cut the risk of getting HIV by up to 90%, depending on how faithfully users take the pill daily. There is still a margin of error if the user skips a pill. Researchers at GlaxoSmithKline (GSK) are testing...
What You Need to Know About Sangamo Biosciences' Surge
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 10, 5:00PM CDT
Sangamo Biosciences' promising early stage HIV drug SB-728-T may someday change how doctors treat patients. Results from a small, 14 person phase 1 trial suggest that while the drug doesn't eradicate HIV from patients, it may someday offer patients...
e-Nicotine Technology to Bring Electronic Nicotine Delivery Products to Market to Address Key Unmet Needs for Smokers and the Public Health Community
Business Wire - Mon Mar 10, 9:09AM CDT
e-Nicotine Technology (eNT) today announced details regarding its family of products aimed at helping smokers as they transition off of combustible cigarettes. Having recently completed clinical trials in nearly 100 smokers and showing rapid (within 1-minute), dramatic (up to 83% reduction) and sustained smoking urge reduction, eNT is moving forward toward the launch of its family of state-of-the-art electronic nicotine delivery products.
Better Dividend: GlaxoSmithKline vs. AbbVie
Dan Carroll, The Motley Fool - Motley Fool - Thu Mar 13, 1:30PM CDT
Big pharma's one of the best industries for investors hungry for high-yielding dividends. Some of the biggest stocks in this sector offer great dividends and stable cash flows, and both GlaxoSmithKline and AbbVie rank among the top names in the...
Appointments, Regulatory Approvals, Conference Participation Schedule, Acquisitions, and Increased Stake - Analyst Notes on Perrigo, Zoetis, ISIS, GSK, and AstraZeneca
PR Newswire - Thu Mar 13, 7:31AM CDT
Today, Analysts Review released its analysts' notes regarding Perrigo Company (NYSE: PRGO), Zoetis Inc. (NYSE: ZTS), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), GlaxoSmithKline plc (NYSE: GSK), and AstraZeneca plc (NYSE: AZN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Patient Recruitment Completes in Landmark RELVAR(R)/BREO(R) ELLIPTA(R) Study to Understand Mortality and MorbidITy (SUMMIT) in COPD
Marketwire - Thu Mar 13, 7:02AM CDT
GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that recruitment of patients into the "Study to Understand Mortality and MorbidITy", known as SUMMIT, has completed enrolment. The aim of this study, which has now enrolled approximately 16,000 patients, is to determine the impact of Relvar(R)/Breo(R) Ellipta(R) (fluticasone furoate 'FF'/vilanterol 'VI') on all cause mortality amongst patients with moderate chronic obstructive pulmonary disease (COPD) who have cardiovascular disease (CVD) or are at increased risk for CVD.
Concise Analysis of the International Orphan Drugs Industry
M2 - Thu Mar 13, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdwn77/orphan_drugs) has announced the addition of the "Concise Analysis of the International Orphan Drugs Industry " report to their offering. This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Japan, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 113 companies including many key and niche players such as: - AbbVie Inc. - Actelion Pharmaceuticals Ltd. - Amgen Inc. - AstraZeneca plc - Bayer HealthCare AG - Biogen Idec Inc. - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Celgene Corporation - CEL-SCI Corporation - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Johnson & Johnson - Merck & Co. Inc. - Merck Serono International S.A. - Novartis AG - Pfizer Inc. - Recordati S.p.A. - Orphan Europe - Sanofi SA - Genzyme Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers And Inhibitors 3. Challenges To Orphan Drug Development 4. Current Market Trends 5. Breakthroughs In Orphan Disease Treatment - A Ray Of Hope 6. Regulatory Scenario 7. Product Overview 8. Recent Orphan Designations & Approvals 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Japan 3. Europe 4. Rest Of World IV. Competitive Landscape Total Companies Profiled: 113 (including Divisions/Subsidiaries - 121) - The United States (61) - Canada (4) - Japan (9) - Europe (42) - France (8) - Germany (3) - The United Kingdom (4) - Italy (4) - Rest of Europe (23) - Asia-Pacific (Excluding Japan) (3) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/kd...phan_drugs
Concise Analysis of the International Oral Hygiene Market - Forecast to 2016
M2 - Thu Mar 13, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dqpd5c/global_oral) has announced the addition of the "Concise Analysis of the International Oral Hygiene Market - Forecast to 2016" report to their offering. One of the main trends witnessed in the Global Oral Hygiene market is the increase in mergers and acquisitions. Vendors are currently opting for the acquisitive route to increase their global presence, expand their product portfolio, and achieve economies of scale in manufacturing. Therefore, they are able to focus better on product innovation and increase their profit margins by collaborating with each other. For instance, Colgate-Palmolive acquired complete stakes of Professional Oral care Products Ltd., a Goa based firm manufacturing and supplying toothpaste to the company in 2010. To venture into new emerging countries, giant vendors of oral hygiene products can merge into or acquire small local vendors thus, gaining more market share. According to the report, one of the main factors driving the market is the increasing demand for age specific products. Fluoride containing mouthwashes are made specifically for adults as they can be harmful to children because there are chances that children might ingest it. Further, the report states that one of the main challenges is the increase in product recalls. For instance, in May 2011, Sensodyne Repair and Protect brand of GSK had to recall thousands of toothpaste tubes from the market as they found some grittiness in the paste that led to bleeding gums. The report also includes a discussion of the other vendors operating in this market. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Market Segmentation 8. Distribution Channel 9. Geographical Segmentation 10. Key Leading Countries 11. Vendor Landscape 12. Buying Criteria 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Key Vendor Analysis Companies Mentioned: - Colgate-Palmolive Co. - GlaxoSmithKline plc - Johnson & Johnson Inc. - Procter& Gamble Co. - Chattem Inc. - Dentsply International Inc. - Lion Corp. - Unilever plc. For more information visit http://www.researchandmarkets.com/research/dq...lobal_oral
Pharmacovigilance Market Research Report - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Thu Mar 13, 4:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rs95v7/pharmacovigilance) has announced the addition of the "Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. A rising tide of regulatory expectations, tougher inspection regime and instant need of patient reporting has provided the much needed impetus for the growth of the pharmacovigilance market. An upsurge in number of acute and chronic diseases has consequently led to a rise in number of drug consumption, which has also elicited a growth in the number of adverse drug events and drug toxicity cases. Moreover, several high-profile safety issues, regulatory warnings, large volume of events to be reviewed along with negative media coverage have compelled the pharmaceutical players to take support of various outsourcing services. There are two major outsourcing services opted by these pharmaceutical players i.e. traditional CROs and BPOs. These outsourcing services not only provide cost savings but also helps in bringing process efficiency. Pharmaceutical companies are now forming long term partnership with the CROs and BPOs to share the costs involved in PV process right from drug discovery to post marketing approvals. In addition, PV requires skilled resources with excellent language skills and strong knowledge pertaining to case reporting. The research report on pharmacovigilance provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of pharmacovigilance market on the bases of clinical trials phases i.e. Phase I to III and post marketing surveillance (PMS). We have also mapped the trend for preference of the pharmaceutical players for in-house and outsourcing in our chapter by type of service. The global pharmacovigilance market has been segmented based on all the above mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in term of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has also been provided along with market size estimations. The report exclusively studies the aforementioned segments with respect to geography. Under geographic section we have covered four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (ROW). The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global pharmacovigilance market. The section also covers opportunities and market attractiveness analysis of the geographical regions. The report concludes with the competitive landscape and company profiles of major market players. These market players have been profiled on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Key Topics Covered: Introduction Executive Summary Global Pharmacovigilance Market Dynamics Global Pharmacovigilance Market, by Clinical Trial Phases Global Pharmacovigilance Market, By Type of Methods Global Pharmacovigilance Market, by Type of Service Providers Global Pharmacovigilance Market, by Geography Global Pharmacovigilance Market Share Analysis Recommendations Company Profiles List of Figures List of Tables Companies Mentioned - Accenture, Plc - Bristol-Myers Squibb - Clinquest Group B.V. - Cognizant Technology Solutions - Covance, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline (GSK) - iGATE Corporation - iMEDGlobal Corporation - inVentiv Health Inc. - ICON, Plc - Infosys - Johnson and Johnson - Novartis International AG - OptumInsight, Inc. - PRA International, Inc. - Parexel International Corporation - Pfizer, Inc. - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Quantum Solutions India - Quintiles Transnational Corporation - Sanofi Aventis - Synowledge LLC - United BioSource Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/rs...ovigilance About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Looking for Bargain Biotechs? Consider Small-Cap Vaccine Makers
George Budwell, The Motley Fool - Motley Fool - Wed Mar 12, 5:30PM CDT
Growth and value are two words that have completely fallen out of the biotech lexicon of late. The adjectives 'bubble' and 'expensive' have instead taken their place, when investors talk biotech. And with the average biotech price to earnings ratio...
Watch for GlaxoSmithKline to Potentially Rebound After Falling 1.20% Yesterday
Comtex SmarTrend(R) - Wed Mar 12, 5:26PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $54.83 to a high of $55.23. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $55.12 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Look for Shares of GlaxoSmithKline to Potentially Rebound after Yesterday's 1.20% Sell Off
Comtex SmarTrend(R) - Wed Mar 12, 5:25PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $54.83 to a high of $55.23. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $55.12 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Glaxo Strengthens Indian Presence - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 5:25PM CDT
GlaxoSmithKline increased its holding in its pharmaceuticals subsidiary in India to 75% through a voluntary open offer.
Bright Outlook at Ligand - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 10:30AM CDT
Ligand provided a rosy outlook at the 2014 Roth Healthcare conference.
The Saudi Arabian Healthcare Sector is Anticipated to Expand at a CAGR of Around 8.7% During 2013-2017
M2 - Wed Mar 12, 10:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/npc4rs/saudi_arabian) has announced the addition of the "Saudi Arabian Healthcare Outlook to 2017" report to their offering. On the back of rising population, prevalence of lifestyle changes & infectious diseases, longer life expectancy & improving healthcare infrastructure, among others, Saudi Arabian Healthcare Sector is witnessing a significant growth over the past few years. The government and health regulatory authorities in the country have been taking keen interest in developing and enhancing healthcare infrastructure for increased accessibility. This report is an outcome of extensive research and analysis of the Saudi Arabian Healthcare Industry. It provides an in-depth analysis of the contributions by MoH, private and other public sectors to the country's healthcare industry, which includes study of existing healthcare infrastructure; hospital beds capacity and forecasted demand; healthcare workforce; etc. for each segment. Also, the research analyzes various crucial factors, like medical test rates in private hospitals and consultancy fees to provide an in-depth knowledge about the industry to potential investors. The report further studies the Kingdom's medical devices and pharmaceuticals market. In the coming years, the country's pharmaceutical industry is expected to witness strong growth. The authors found that this industry was one of the highly prolific healthcare sectors due to rising prevalence of lifestyle diseases, like obesity, diabetes and cardiovascular ailments. The report includes detailed information about the domestic pharmaceutical market and the country's imports. In medical device segment, presently the country has low manufacturing capabilities, but the market is growing tremendously, supported by government. The report further discusses how growing consolidation, application of e-health and m-health, and favorable regulations are influencing the industry's growth. It also covers a regional analysis of the country's healthcare industry to give an idea about the region, exhibiting better opportunity for investment to customers. Finally, the study covers a competitive landscape, which includes the country's prominent pharmaceutical players and hospitals, to help clients understand the market, its structure and progress in the coming years. Companies Mentioned: - GlaxoSmithKline - Pfizer Inc. - SPIMACO - Sanofi-Aventis - TABUK Pharmaceutical Manufacturing For more information visit http://www.researchandmarkets.com/research/np...di_arabian About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update
M2 - Wed Mar 12, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p5vwnh/pharmapoint) has announced the addition of the "PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update" report to their offering. New Serogroup B Vaccines to Claim Half of Meningococcal Vaccines Market by 2022 Upcoming and long-awaited market entries for Novartis' Bexsero and Pfizer's MnB rLP2086 will prompt significant growth in the meningococcal vaccines market over the next decade, states research and consulting firm The authors. According to the report, the arrival of these eagerly awaited serogroup B vaccine will drive combined revenue for meningococcal vaccines across the US, France, Germany, Italy, Spain, the UK, Japan, Australia, and Brazil, from $1.2bn in 2012 to just over $2bn in 2022, increasing by 65%. Novartis' Bexsero, which received approval from the European Medicines Agency (EMA) in January, is forecast to produce global sales of over $330m by 2022, while Pfizer's MnB rLP2086, which is expected to launch in the US in 2017 and in the EU the following year, is forecast to reach total revenue of over $700m by 2022. Combined, these two products are expected to dominate the meningococcal vaccines market by the end of the forecast period, accounting for a 52% share. According to Dr Christopher Pace, The authors's analyst covering infectious disease: Despite legitimate concerns from policymakers regarding the cost-effectiveness of adding an additional vaccine to already-crowded immunization schedules, serogroup B incorporation will be well received by prescribers and patients, alike. Novartis and Pfizer are expected to dominate this segment of the market, with their respective products responsible for the majority of global market growth over the next decade. The authors's report states that the cost-effectiveness of meningococcal vaccines is a universal barrier to global market growth, with the inherently high cost per dose and relatively low incidence rates of meningococcal disease leading to increased government skepticism in the face of new vaccine launches and immunization program expansions. Dr Pace believes that while these concerns are not expected to significantly prohibit the adoption of serogroup B vaccines, such as Bexsero and MnB rLP2086, government assessment of cost-effectiveness is considered to be a primary determinant of a vaccine's commercial success. Key Topics Covered - Table of Contents - Introduction - Disease Overview - Epidemiology - Disease Management - Competitive Assessment - Opportunity and Unmet Need - Pipeline Assessment - Current and Future Players - Market Outlook - Appendix Companies Mentioned - Baxter - GlaxoSmithKline - Novartis - Nuron Biotech - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/p5...harmapoint About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
As Raleigh NC Makes the Forbes List of America's Fastest Growing Cities, Mark Steward, Realtor with DT&Company, Says, "Come for the Jobs, Stay for the Lifestyle"
PRWeb - Wed Mar 12, 3:40AM CDT
With annual job growth of 2.9%, people are migrating to Research Triangle Park also known as the RTP in the Raleigh-Durham area in North Carolina. Thousands of families are taking a hard look at this region and planning their relocation to the Triangle. This growth can be attributed to many surprising advantages that the region offers. According to Forbes, after talking with New York-based research firm Ipreo, it became clear the company was looking to expand into a new office, and searched nation-wide for the perfect location. "The primary goal was access to talent," says O'Hara Macken, an EVP and managing director, "and the [Research] Triangle was our top choice in the U.S." Ipreo, which provides data, software, and intelligence to the capital markets and public companies, opened an outpost in Raleigh, N.C. last year, moved 70 employees from New York and Bethesda, Md., hired 80 North Carolina locals, and plans to hire 100 more. (Forbes, The best place for business and careers, February 14, 2014)
The Cancer Monoclonal Antibodies Market is Estimated at US$ 24 Billion, and is expected to Grow to Around US$ 34 Billion by 2017
M2 - Tue Mar 11, 10:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ghw3bj/cancer_monoclonal) has announced the addition of the "Cancer Monoclonal Antibodies Market Forecast to 2017" report to their offering. Cancer, one of the leading causes of death worldwide, affected approximately 13 Million people in 2012 and this figure is expected to grow to 17 Million by 2020. The dramatic increase in the size of the potential cancer market has prompted pharmaceutical players to invest in the oncology sector with major focus on monoclonal antibodies. Monoclonal antibodies identify cancer cells, bind to proteins on their surface, and stimulate an immune response so are very specific to targets. Various monoclonal antibodies for treatment of cancer are available in the market and many more are in the pipeline. The report, in particular, provides an insight to the global burden of cancer, with detailed breakdown of incidences by type and geography. It not only estimates the current burden but also makes future predictions. There is an exhaustive overview of the monoclonal technology, helping the client understand the various types of antibodies and the diverse types of cancer therapies which make use of mAbs. In this report, the authors have profiled every anti-cancer monoclonal antibody available in the market and estimated the current and future market of five of them. The report covers major trends which are driving the current market and a country level analysis of the status of cancer mAbs. Through this pipeline analysis of the various mAbs, it has been revealed that majority of the mAbs in the pipeline are in phase III trials with most of them devoted to Solid Tumor, Lung Cancer, Breast Cancer, and NHL. The approval of these drugs will drive a major change in the market in terms of market share of current drugs. Companies Mentioned: - Amgen - Bristol-Myers Squibb - Eli Lilly - Genmab - GlaxoSmithKline - Roche - Seattle Genetics - Spectrum Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/gh...monoclonal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Wider Q4 Loss at Dynavax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:10AM CDT
Dynavax Technologies reported a loss of 9 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 7 cents.
Awards Recognise GlaxoSmithKline, Henkel, MondelA"z International, Tesco and the US Department of Veterans Affairs for e-Invoicing Best Practice
PR Newswire Europe - Tue Mar 11, 4:32AM CDT
LONDON, March 11, 2014 /PRNewswire/ --
A HIV shot could replace pills
at Investor's Business Daily - Mon Mar 10, 5:46PM CDT
Daily pills like Gilead's (GILD) Truvada can cut the risk of getting HIV by up to 90%, depending on how faithfully users take the pill daily. There is still a margin of error if the user skips a pill. Researchers at GlaxoSmithKline (GSK) are testing...
What You Need to Know About Sangamo Biosciences' Surge
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 10, 5:00PM CDT
Sangamo Biosciences' promising early stage HIV drug SB-728-T may someday change how doctors treat patients. Results from a small, 14 person phase 1 trial suggest that while the drug doesn't eradicate HIV from patients, it may someday offer patients...
e-Nicotine Technology to Bring Electronic Nicotine Delivery Products to Market to Address Key Unmet Needs for Smokers and the Public Health Community
Business Wire - Mon Mar 10, 9:09AM CDT
e-Nicotine Technology (eNT) today announced details regarding its family of products aimed at helping smokers as they transition off of combustible cigarettes. Having recently completed clinical trials in nearly 100 smokers and showing rapid (within 1-minute), dramatic (up to 83% reduction) and sustained smoking urge reduction, eNT is moving forward toward the launch of its family of state-of-the-art electronic nicotine delivery products.
(0)
(0)GlaxoSmithKline PLC (GSK) Stock Research Links
Scroll down for more posts ▼